Fig. 1
From: Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1
Correlation of the K-index with response to initial pembrolizumab therapy in patients with NSCLC. (a) PFS curves of patients receiving the first-line treatment. The blue line indicates K-index ≥192, and the red line indicates a K-index < 192. (b) OS curves of patients receiving first-line treatment. Statistical significance was assessed using the log-rank test. NSCLC, non-small cell lung cancer; OS, overall survival; mOS, median OS; PFS, progression-free survival; mPFS, median PFS